FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2835697027> ?p ?o ?g. }

• W2835697027 abstract "Direct-acting antivirals (DAA) have dramatically increased HCV cure rates with minimal toxicity in HIV-HCV co-infected patients. This study aimed to compare the socio-behavioral characteristics of patients initiating pegylated-interferon (PEG-IFN)-based HCV treatment with those of patients initiating DAA-based treatment.ANRS CO13 HEPAVIH is a national multicenter prospective cohort started in 2005, which enrolled 1,859 HIV-HCV co-infected patients followed up in French hospital outpatient units. Both clinical/biological and socio-behavioral data were collected during follow-up. We selected patients with socio-behavioral data available before HCV treatment initiation.A total of 580 patients were included in this analysis. Of these, 347 initiated PEG-IFN-based treatment, and 233 DAA-based treatment. There were significant differences regarding patient mean age (45 years±6 for the PEG-IFN group vs. 52 years±8 for the DAA group, p<0.001), unstable housing (21.4% vs. 11.2%, p = 0.0016), drug use (44.7% vs. 29.6%, p = 0.0003), regular or daily use of cannabis (24.3% vs. 15.6%, p = 0.0002), a history of drug injection (68.9% vs 39.0%, p<0.0001) and significant liver fibrosis (62.4% vs 72.3%, p = 0.0293). In multivariable analysis, patients initiating DAA-based treatment were older than their PEG-IFN-based treatment counterparts (aOR = 1.17; 95%CI [1.13; 1.22]). Patients receiving DAA treatment were less likely to report unstable housing (0.46 [0.24; 0.88]), cannabis use (regular or daily use:0.50 [0.28; 0.91]; non-regular use: 0.41 [0.22; 0.77]), and a history of drug injection (0.19 [0.12; 0.31]).It is possible that a majority of patients who had socio-economic problems and/or a history of drug injection and/or a non-advanced disease stage were already treated for HCV in the PEG-IFN era. Today, patients with unstable housing conditions are prescribed DAA less frequently than other populations. As HCV treatment is prevention, improving access to DAA remains a major clinical and public health strategy, in particular for individuals with high-risk behaviors." @default.
• W2835697027 created "2018-07-19" @default.
• W2835697027 creator A5001041075 @default.
• W2835697027 creator A5007096310 @default.
• W2835697027 creator A5013523343 @default.
• W2835697027 creator A5014748606 @default.
• W2835697027 creator A5016962180 @default.
• W2835697027 creator A5042866367 @default.
• W2835697027 creator A5044031344 @default.
• W2835697027 creator A5045734541 @default.
• W2835697027 creator A5050819020 @default.
• W2835697027 creator A5079327362 @default.
• W2835697027 creator A5079614854 @default.
• W2835697027 creator A5085208411 @default.
• W2835697027 date "2018-07-05" @default.
• W2835697027 modified "2023-10-16" @default.
• W2835697027 title "Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients" @default.
• W2835697027 cites W111460370 @default.
• W2835697027 cites W1686027635 @default.
• W2835697027 cites W1895949411 @default.
• W2835697027 cites W1969094977 @default.
• W2835697027 cites W1969473132 @default.
• W2835697027 cites W1976451391 @default.
• W2835697027 cites W1979042581 @default.
• W2835697027 cites W1980771473 @default.
• W2835697027 cites W2026067734 @default.
• W2835697027 cites W2034509002 @default.
• W2835697027 cites W2039302135 @default.
• W2835697027 cites W2046345361 @default.
• W2835697027 cites W2049143320 @default.
• W2835697027 cites W2055301074 @default.
• W2835697027 cites W2058262873 @default.
• W2835697027 cites W2062957362 @default.
• W2835697027 cites W2064387090 @default.
• W2835697027 cites W2065214690 @default.
• W2835697027 cites W2094287953 @default.
• W2835697027 cites W2094971471 @default.
• W2835697027 cites W2098521993 @default.
• W2835697027 cites W2098658501 @default.
• W2835697027 cites W2101368910 @default.
• W2835697027 cites W2115399503 @default.
• W2835697027 cites W2117027295 @default.
• W2835697027 cites W2145623055 @default.
• W2835697027 cites W2145994537 @default.
• W2835697027 cites W2166118716 @default.
• W2835697027 cites W2167768758 @default.
• W2835697027 cites W2169923344 @default.
• W2835697027 cites W2170619054 @default.
• W2835697027 cites W2177840336 @default.
• W2835697027 cites W2293984687 @default.
• W2835697027 cites W2341078895 @default.
• W2835697027 cites W2345381660 @default.
• W2835697027 cites W2460814285 @default.
• W2835697027 cites W2491362337 @default.
• W2835697027 cites W2519148602 @default.
• W2835697027 cites W2584646877 @default.
• W2835697027 cites W2585559588 @default.
• W2835697027 cites W2591264818 @default.
• W2835697027 cites W2606566374 @default.
• W2835697027 cites W2767575038 @default.
• W2835697027 doi "https://doi.org/10.1371/journal.pone.0199874" @default.
• W2835697027 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6033422" @default.
• W2835697027 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29975764" @default.
• W2835697027 hasPublicationYear "2018" @default.
• W2835697027 type Work @default.
• W2835697027 sameAs 2835697027 @default.
• W2835697027 citedByCount "3" @default.
• W2835697027 countsByYear W28356970272020 @default.
• W2835697027 countsByYear W28356970272022 @default.
• W2835697027 countsByYear W28356970272023 @default.
• W2835697027 crossrefType "journal-article" @default.
• W2835697027 hasAuthorship W2835697027A5001041075 @default.
• W2835697027 hasAuthorship W2835697027A5007096310 @default.
• W2835697027 hasAuthorship W2835697027A5013523343 @default.
• W2835697027 hasAuthorship W2835697027A5014748606 @default.
• W2835697027 hasAuthorship W2835697027A5016962180 @default.
• W2835697027 hasAuthorship W2835697027A5042866367 @default.
• W2835697027 hasAuthorship W2835697027A5044031344 @default.
• W2835697027 hasAuthorship W2835697027A5045734541 @default.
• W2835697027 hasAuthorship W2835697027A5050819020 @default.
• W2835697027 hasAuthorship W2835697027A5079327362 @default.
• W2835697027 hasAuthorship W2835697027A5079614854 @default.
• W2835697027 hasAuthorship W2835697027A5085208411 @default.
• W2835697027 hasBestOaLocation W28356970271 @default.
• W2835697027 hasConcept C118552586 @default.
• W2835697027 hasConcept C126322002 @default.
• W2835697027 hasConcept C142462285 @default.
• W2835697027 hasConcept C151730666 @default.
• W2835697027 hasConcept C188816634 @default.
• W2835697027 hasConcept C203014093 @default.
• W2835697027 hasConcept C2522874641 @default.
• W2835697027 hasConcept C2776408679 @default.
• W2835697027 hasConcept C2776455275 @default.
• W2835697027 hasConcept C2776461080 @default.
• W2835697027 hasConcept C2777056318 @default.
• W2835697027 hasConcept C2779343474 @default.
• W2835697027 hasConcept C2780040827 @default.
• W2835697027 hasConcept C3013748606 @default.
• W2835697027 hasConcept C71924100 @default.
• W2835697027 hasConcept C72563966 @default.

• next